Cosette Pharma’s RYANODEX® (dantrolene sodium) for Injectable Suspension, Fully Stocked and Available
Business Wire•10/11/2026•08:00 ET
0
Key Highlights
- ➤RYANODEX fully stocked across U.S. and international markets
- ➤Cosette acquired RYANODEX from Eagle Pharmaceuticals in June 2026
- ➤Cosette completed RYANODEX supply chain transition successfully
Expert Statements
Apurva Saraf, President and Chief Executive Officer of Cosette Pharmaceuticals
“Our acquisition of RYANODEX® reflects Cosette's commitment to expanding access to important medicines and ensuring the infrastructure is in place to support them.”
Apurva Saraf, President and Chief Executive Officer of Cosette Pharmaceuticals
“Our ability to successfully integrate RYANODEX® and ensure a dependable supply demonstrates the strength of our organization and our focus on delivering for healthcare providers and patients.”
Brad Leonard, Vice President, Commercial Operations at Cosette Pharmaceuticals
“Healthcare providers depend on having the medicines they need, when they need them.”
Brad Leonard, Vice President, Commercial Operations at Cosette Pharmaceuticals
“Our priority is to ensure hospitals and healthcare providers have dependable access to RYANODEX®, so they can focus on what matters most: delivering timely care to patients.”
Cosette Pharma’s RYANODEX(®) (dantrolene sodium) for Injectable Suspension, Fully Stocked and Available
– – Following its acquisition from Eagle Pharmaceuticals and successful supply chain transition, Cosette maintains robust inventory to serve healthcare providers in the U.S. and international markets – –
Get started
Create a free account to read the full story.